Prof.Antonio Ceriello 

The Lessons We’ve Learned from COVID 19 pandemic What to do next

Prof.Mohamed Khattab 

Empagliflozin and CV Renal Benefits Across The Diabetes Continuum

Prof.Ibrahim Elebrashy 

Diabetic Neuropathy

Prof.Hossam Arafa Ghazi 

role of horse technology in 2 types

Prof.Hesham El Gayar 

Dapagliflozin Portfolio , a game Changer

Prof.Naglaa El Sayed 

CGM impact on diabetic complications

Prof.Nabil El Kafrawy 

Modulating cardio renal outcomes in patients with diabetes

Prof.Mohamed Abdel Raouf Triglycerides An Emerging Target in Management of Diabetic Dyslipidemia

Prof.Khalifa Abdallah 

Combination Therapies in T2D What Synjardy Can Add

Prof.Khaled El Hadidi 

Updates in Diabetic retinopathy from ADA 2020

Prof.Ibrahim Elebrashy 

Value of Quadrivalent Influenza Vaccine for Diabetic patients

Prof.Hesham Magd 

Remission in type 1 DM

Prof.Nebojsa M Lalic 

Continuous Glucose Measurement Present and Future

Prof.Nermine Sheriba 

Rosuvastatin Ezetimibe single pill combination the first High Intensity lipid lower

Prof.Samir George 

Linagliptin A simplified Approach in the management of T2D

Prof.Salah Shelbaya 

B Right From The Start

Prof.Thamer Alessa 

Recent Updates in T2DM Management – The CompoSIT Program

Prof.Khalifa Abdallah 

The new generation of insulin

Prof.Ismail Ramadan 

Central insulin resistance and it’s relation to neurological disorders

Prof.Ibrahim Elebrashy 

GLP 1RA Gate to the future

Peof.Ibrahim Elebrashy 

Gliclazide MR new evidence for the benefits of the patients

Prof.Hesham El Gayar 

From dual to triple therapy; what is new

Prof.Hany Ragy 

When and how to screen for cardiovascular complications in diabetics

Prof. Ayman Abou El Magd 

Management of IHD in diabetics

Prof.Tarek El Baz 

Diabetic Kidney Disease Challenges, and new insights

Prof.Silvio E Inzucchi

Comprehensive T2D management from gluco centric to holitic approach

Prof.Nabil El Naggar

Life and death of B cells innovative implications for therapeutic approaches

Prof.Mohamed Sobhy 

SGLT2i From Prevention to Treatment Cardio perspective

Meet The Experts Session

Prof.Mary Nabil

Diabetes and Brain EASD 2020

Opening Cermoney

Prof.Nermine Sheriba 

What Are Pcsk9 is and When To Use Them

Prof.Nermine Sheriba 

Debate Which is the winner GLP 1 RA or SGLT2

Prof.Nebojsa M Lalic 

Cvot Results Messages and Dilemmas

Prof.Nabil El Kafrawy 

Debate Which is the winner GLP 1 RA or SGLT2

Prof.Salah Shelbaya 

Management of newly diagnosed T2DM patients

Prof.Nabil El Kafrawy 

A different approach in hypertension management

Prof.Nabil El Kafrawy 

10 Years with DPP 4 Inhibition – Role of Sitagliptin in different T2DM population

Prof.Mohamed Khattab 

SUs what's new

Prof.Mohamed Abolgheit 

Liraglutide 3 0 mg filling the gap in obesity management

Prof.Martin Haluzik 

Introducing Soliqua Iglarlixi

Prof.Thamer Alessa

Recent Updates in T2DM Management – The CompoSIT Program

Prof.Nabil El Kafrawy 

Modulating cardio renal outcomes in patients with diabetes

Prof.Hesham El Hefnawy 

SGLT 2 I Moving from safety to benefits

Prof.Mohamed Reda Halawa 

Who benefits most from an early combination treatment approach for type II Diabe

Prof.Shaimaa Zewain 

Type 2 Diabetes, How much of an Autoimmune origin

Prof.Haytham Badr 

Management of DM in chronic liver disease

Prof.Iman Tohamy 

Diabetes in the elderly

Prof.Maha Youssef 

Diabetes and the kidney

Prof.Moustafa Bakrey 

Hamed Osteoporosis in Diabetes Mellitus

Prof.Shaimaa Fathi 

Diabetes and the liver

Prof.Islam Anan

Economic Burden of Diabetes in Egypt 1